Pluristem Story

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;'>PT</div>
PSTI -- USA Stock  

USD 9.27  0.04  0.43%

While some millenniums are indifferent towards healthcare space, it makes sense to concentrate on Pluristem Therapeutics in terms of its current potentials. As expected, Pluristem Therapeutics is starting to reaffirm its true potential as stockholders are becoming more and more confident in the future outlook. The returns on the market and returns on Pluristem Therapeutics appear somewhat related for the last few months. Fragile forward indicators of the company may also hint to signs of long-run losses for Pluristem stockholders. Pluristem Therapeutics is scheduled to announce its earnings tomorrow. The stock goes through an active upward rally.
Published over a month ago
View all stories for Pluristem Therapeutics | View All Stories
Will Pluristem Therapeutics (NASDAQ:PSTI) price continue to rise in October?
This firm's average rating is Buy from 3 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Pluristem Therapeutics market sentiment investors' perception of the future value of Pluristem. Let us look at a few aspects of Pluristem technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Pluristem Therapeutics. In general, we focus on analyzing Pluristem Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pluristem Therapeutics's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Pluristem Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for Pluristem Therapeutics, we also check how macroeconomic factors affect Pluristem Therapeutics price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

How does Pluristem Stands against Peers?

Analyzing Pluristem Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Pluristem Therapeutics across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Pluristem Therapeutics Competition Details

How Pluristem utilizes its cash?

To perform a cash flow analysis of Pluristem Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Pluristem Therapeutics is receiving and how much cash it distributes out in a given period. The Pluristem Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Purchase by Clover Wolf Capita of 20000 shares of Pluristem Therapeutics

Legal trades by Pluristem Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Pluristem insider trading alert for perchase of common stock by Clover Wolf Capita, the corporate stakeholder, on 29th of October 2020. This event was filed by Pluristem Therapeutics In with SEC on 2020-10-29. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Pluristem Therapeutics Semi Variance

Pluristem Therapeutics has current Semi Variance of 12.74. Semi-variance provides a good measure of downside volatility for equity or a portfolio. It is similar to variance, but it only looks at periods where the returns are less than the target or average level.

Semi-variance is the square of semi-deviation. Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.

Semi Variance 
SUM = Summation notation
RET DEV = Actual return deviation over selected period
N(ZERO) = Number of points with returns less than zero
Let's now compare Pluristem Therapeutics Semi Variance to its closest peers:

Another 3 percent rise for Pluristem Therapeutics

The coefficient of variation is down to 1326.13 as of today. As of the 25th of September, Pluristem Therapeutics holds the Coefficient Of Variation of 1326.13, semi deviation of 3.57, and Risk Adjusted Performance of 0.0936. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pluristem Therapeutics, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Pluristem Therapeutics, which can be compared to its competitors. Please check Pluristem Therapeutics jensen alpha and downside variance to decide if Pluristem Therapeutics is priced some-what accurately, providing market reflects its current price of 9.66 per share. Given that Pluristem Therapeutics has jensen alpha of 0.3508, we recommend you to check out Pluristem Therapeutics's recent market performance to make sure the company can sustain itself at a future point.

While many of the other players under the biotechnology industry are still a bit expensive, Pluristem Therapeutics may offer a potential longer-term growth to stockholders. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to drop some or all of your Pluristem Therapeutics holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Pluristem Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Pluristem Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to